High-resolution crystal structure of the human CB1 cannabinoid receptor

Nature

Volumn 540, Issue 7634, 2016, Pages 602-606

  Shao, Zhenhua ^a   Yin, Jie ^a   Chapman, Karen ^a   Grzemska, Magdalena ^a   Clark, Lindsay ^a   Wang, Junmei ^a   Rosenbaum, Daniel M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; RIMONABANT; TARANABANT;

BIOPHYSICS; CRYSTAL STRUCTURE; CRYSTALLIZATION; GENETIC ENGINEERING; INHIBITOR; OPTIMIZATION; PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DISULFIDE BOND; EXTRACELLULAR SPACE; INHIBITION CONSTANT; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN ENGINEERING; PROTEIN STRUCTURE; THERMOSTABILITY;

EID: 85015831861     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature20613     Document Type: Article

References (50)

1. Mechoulam, R., Parker, L. A. The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21-47 (2013).
2. Lynch, M. E., Ware, M. A. Cannabinoids for the treatment of chronic non-cancer pain: An updated systematic review of randomized controlled trials. J. Neuroimmune Pharmacol. 10, 293-301 (2015).
3. Reddy, D. S., Golub, V. M. The pharmacological basis of cannabis therapy for epilepsy. J. Pharmacol. Exp. Ther. 357, 45-55 (2016).
4. Kim, J., Li, Y., Watkins, B. A. Endocannabinoid signaling and energy metabolism: A target for dietary intervention. Nutrition 27, 624-632 (2011).
5. Pertwee, R. G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: 9-tetrahydrocannabinol, cannabidiol and 9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199-215 (2008).
6. Vemuri, V. K., Makriyannis, A. Medicinal chemistry of cannabinoids. Clin. Pharmacol. Ther. 97, 553-558 (2015).
7. Howlett, A. C., et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 (Suppl. 1), 345-358 (2004).
8. Wilson, R. I., Nicoll, R. A. Endocannabinoid signaling in the brain. Science 296, 678-682 (2002).
9. Fowler, C. J. Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J. 280, 1895-1904 (2013).
10. Tam, J., et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 16, 167-179 (2012).
11. Jourdan, T., et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat. Med. 19, 1132-1140 (2013).
12. Gaoni, Y., Mechoulam, R. Isolation, structure, partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647 (1964).
13. Janero, D. R., Makriyannis, A. Cannabinoid receptor antagonists: Pharmacological opportunities, clinical experience, translational prognosis. Expert Opin. Emerg. Drugs 14, 43-65 (2009).
14. Yin, J., et al. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat. Struct. Mol. Biol. 23, 293-299 (2016).
15. D'Antona, A. M., Ahn, K. H., Kendall, D. A. Mutations of CB1 T210 produce active and inactive receptor forms: Correlations with ligand affinity, receptor stability, cellular localization. Biochemistry 45, 5606-5617 (2006).
16. González-Mariscal, I., et al. Human CB1 receptor isoforms, present in hepatocytes and-cells, are involved in regulating metabolism. Sci. Rep. 6, 33302 (2016).
17. Andersson, H., D'Antona, A. M., Kendall, D. A., Von Heijne, G., Chin, C. N. Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail. Mol. Pharmacol. 64, 570-577 (2003).
18. Rosenbaum, D. M., et al. GPCR engineering yields high-resolution structural insights into 2-adrenergic receptor function. Science 318, 1266-1273 (2007).
19. Hanson, M. A., et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851-855 (2012).
20. Hurst, D. P., et al. A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J. Biol. Chem. 285, 17954-17964 (2010).
21. Fay, J. F., Farrens, D. L. The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity. Biochemistry 52, 8286-8294 (2013).
22. Chrencik, J. E., et al. Crystal structure of antagonist bound human lysophosphatidic acid receptor 1. Cell 161, 1633-1643 (2015).
23. Palczewski, K., et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-745 (2000).
24. Park, J. H., Scheerer, P., Hofmann, K. P., Choe, H.-W., Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183-187 (2008).
25. Fong, T. M., et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther. 321, 1013-1022 (2007).
26. Kapur, A., et al. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: Evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol. Pharmacol. 71, 1512-1524 (2007).
27. Lin, L. S., et al. Conformational analysis and receptor docking of N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]oxypropanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. J. Med. Chem. 51, 2108-2114 (2008).
28. Shim, J.-Y., Bertalovitz, A. C., Kendall, D. A. Probing the interaction of SR141716A with the CB1 receptor. J. Biol. Chem. 287, 38741-38754 (2012).
29. Sitkoff, D. F., et al. Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383. Eur. J. Pharmacol. 651, 9-17 (2011).
30. Hurst, D. P., et al. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 62, 1274-1287 (2002).
31. McAllister, S. D., et al. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: The importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem. 279, 48024-48037 (2004).
32. Shim, J.-Y., Bertalovitz, A. C., Kendall, D. A. Identification of essential cannabinoid-binding domains: Structural insights into early dynamic events in receptor activation. J. Biol. Chem. 286, 33422-33435 (2011).
33. Picone, R. P., et al. ( )-7-Isothiocyanato-11-hydroxy-1, 1-dimethylheptylhexahy drocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol. Pharmacol. 68, 1623-1635 (2005).
34. Hua, T., et al. Crystal structure of the human cannabinoid receptor CB1. Cell 167, 750-762.e14 (2016).
35. Manglik, A., et al. Structural insights into the dynamic process of 2-adrenergic receptor signaling. Cell 161, 1101-1111 (2015).
36. Console-Bram, L., Marcu, J., Abood, M. E. Cannabinoid receptors: Nomenclature and pharmacological principles. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 4-15 (2012).
37. Price, M. R., et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68, 1484-1495 (2005).
38. Hofmann, L., Gulati, S., Sears, A., Stewart, P. L., Palczewski, K. An effective thiol-reactive probe for differential scanning fluorimetry with a standard real-time polymerase chain reaction device. Anal. Biochem. 499, 63-65 (2016).
39. Caffrey, M., Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nat. Protocols 4, 706-731 (2009).
40. Otwinowski, Z., Minor, W. Processing of X-ray data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
41. McCoy, A. J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
42. Horcajada, C., Guinovart, J. J., Fita, I., Ferrer, J. C. Crystal structure of an archaeal glycogen synthase: Insights into oligomerization and substrate binding of eukaryotic glycogen synthases. J. Biol. Chem. 281, 2923-2931 (2006).
43. Emsley, P., Lohkamp, B., Scott, W. G., Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
44. Skubák, P., Murshudov, G. N., Pannu, N. S. Direct incorporation of experimental phase information in model refinement. Acta Crystallogr. D 60, 2196-2201 (2004).
45. Schüttelkopf, A. W., van Aalten, D. M. F. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D 60, 1355-1363 (2004).
46. Baker, N. A., Sept, D., Joseph, S., Holst, M. J., McCammon, J. A. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc. Natl Acad. Sci. USA 98, 10037-10041 (2001).
47. Case, D. A., et al. The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668-1688 (2005).
48. Izaguirre, J. A., Catarello, D. P., Wozniak, J. M., Skeel, R. D. Langevin stabilization of molecular dynamics. J. Chem. Phys. 114, 2090-2098 (2001).
49. Friesner, R. A., et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749 (2004).
50. Friesner, R. A., et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177-6196 (2006).